Skip to main content

Hemophagocytic Lymphohistiocytoses

5
Pipeline Programs
4
Companies
4
Clinical Trials
1 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
1
0
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 4 programs with unclassified modality

On Market (2)

Approved therapies currently available

GAMIFANTApproved
emapalumab-lzsg
Unknown Company
Interferon gamma Blocker [EPC]injection2018
983K Part D
Incyte
JAKAFI XRApproved
ruxolitinib
Incyte
Kinase Inhibitor [EPC]oral2026

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Incyte
IncyteDE - Wilmington
1 program
1
1
JAKAFI XR(Ruxolitinib)Phase 2Small Molecule1 trial
Active Trials
NCT06160791Recruiting36Est. Nov 2029
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
DexamethasonePhase 41 trial
Active Trials
NCT05491304Unknown400Est. Dec 2025
Light Chain Bioscience
Light Chain BioscienceSwitzerland - Geneva
1 program
1
Emapalumab-LzsgPhase 2/3
Swedish Orphan Biovitrum
2 programs
Blood Draws Data CollectionN/A1 trial
Emapalumab-LzsgPHASE_2_31 trial
Active Trials
NCT06047210Completed14Est. Oct 2019
NCT03985423Terminated7Est. Jun 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
UNION therapeuticsDexamethasone
Swedish Orphan BiovitrumEmapalumab-Lzsg
IncyteRuxolitinib
Swedish Orphan BiovitrumBlood Draws Data Collection

Clinical Trials (4)

Total enrollment: 457 patients across 4 trials

NCT05491304UNION therapeuticsDexamethasone

Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis

Start: Sep 2022Est. completion: Dec 2025400 patients
Phase 4Unknown
NCT03985423Swedish Orphan BiovitrumEmapalumab-Lzsg

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH

Start: Jun 2020Est. completion: Jun 20217 patients
Phase 2/3Terminated
NCT06160791IncyteRuxolitinib

Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

Start: Oct 2024Est. completion: Nov 202936 patients
Phase 2Recruiting
NCT06047210Swedish Orphan BiovitrumBlood Draws Data Collection

Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis

Start: Dec 2016Est. completion: Oct 201914 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 457 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.